InMode Committee Concludes Review
Medical technology provider InMode Ltd. announced that the independent transaction committee of its Board of Directors has completed its review. The Israel-based company, which provides innovative medical technologies, did not immediately disclose the findings or purpose of the committee's review.
- The review was initiated in response to a non-binding, unsolicited offer from activist investor Steel Partners Holdings to acquire a 51% controlling stake in InMode for $18.00 per share. This offer represented a 29% premium over the share price before transaction speculation began. - After a comprehensive review with external advisors, the committee concluded that none of the final proposals were adequate or in the best interests of the company and its shareholders, and therefore discontinued the process. - InMode specializes in minimally and non-invasive medical technologies, particularly devices using radiofrequency (RF) for aesthetic procedures like body contouring and skin rejuvenation, serving a niche between laser treatments and full plastic surgery. This positions it within the growing outpatient and private clinic segment of the healthcare market. - The unsolicited offer came after InMode's stock had fallen significantly from its all-time high in November 2021. Steel Partners cited mismanagement and a large cash hoard of over $532 million as reasons for its offer. - The company's financial performance has seen a slowdown, with revenue guidance for 2025 revised downward due to cooling demand for elective aesthetic treatments in North America. However, the company remains profitable with strong gross margins and no significant debt. - This event reflects a broader trend of increased private equity interest in the medical technology sector. In 2024, global healthcare private equity deal value reached an estimated $115 billion, the second-highest total on record, with medtech being a leading segment for deals.
